Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

Fig. 2

Regorafenib 10 mg/kg/day significantly inhibits growth of patient-derived xenografts. The effects of regorafenib 10 mg/kg/day on tumor growth inhibition (a, b, and c), tumor weight (d, e, and f), and representative tumors (g, h, and i) are demonstrated in xenograft models GC17-0409, GC28-1107, and GC09-0109. Data are mean ± standard error (*, p < 0.001)

Back to article page